NEW YORK (GenomeWeb News) – Atossa Genetics said after the close of the market on Thursday that its full-year 2013 revenues grew 31 percent year over year on increased product sales.

The Seattle-based firm recorded $632,558 in total revenues for 2013, up from $481,842 in 2012. While diagnostic testing service revenues slipped to $409,118 from $475,402, product sales rose to $223,440 from $6,440, Atossa said, noting that $205,590 in product sales resulted from the purchase of 10,000 ForeCYTE specimen collection kits by Millennium Healthcare.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.